Abstract: The present disclosure relates to compositions and methods for predicting cancer survival in a subject after receiving a treatment (e.g., allogeneic hematopoietic-cell transplantation). The present disclosure further discloses compositions and methods for treating said subject.

Abstract: The present invention relates to, in part, methods and compositions for reducing the incidence and/or severity of complications associated with IV beta-lactam antibiotic use in allo-HCT recipients, such as aGVHD and VRE colonization and/or VRE bloodstream infection, using beta-lactamase agents.

Abstract: The presently disclosed subject matter provides methods and systems for isolating cells expressing specific constructs. In certain non-limiting embodiments, the system comprises a membrane-bound polypeptide and a soluble polypeptide that is capable of dimerizing with the membrane-bound polypeptide.

Abstract: The presently disclosed subject matter provides compositions and systems for cell-based immunotherapy. In certain non-limiting embodiments, the system comprises a membrane-bound polypeptide and at least one soluble polypeptide that is capable of dimerizing with the membrane-bound polypeptide.

Abstract: Described herein are methods for the treatment of radiation injury by administration of sex steroid inhibitory (SSI) agents.

Abstract: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.

Abstract: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.

Abstract: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.

Abstract: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.

Abstract: Described herein are methods for the treatment of radiation injury by administration of sex steroid inhibitory (SSI) agents.

Abstract: A method and an apparatus are provided for determining T-cell repertoire recovery after allo-HSCT or identifying patients at high risk of infection. Combination of 5?-RACE PCR with deep sequencing was used to quantify TCR diversity in 33 individuals using a single oligonucleotide pair. Analysis of duplicate blood samples revealed highly reproducible detection of expanded TCR clonotypes. After 6 months, recipients of cord blood grafts without anti-thymocyte globulin therapy approximated the TCR diversity of healthy subjects, whereas recipients of T-cell-depleted peripheral blood stem cell grafts had a 28-fold and 14-fold lower CD4+ and CD8+ T-cell diversity, respectively. After 12 months, these differences had leveled out for the CD4+, but not the CD8+ T-cell compartment.